Pfizer Q3 Results - Q3 Top Pharma Company Earnings Reports

View Pfizer's Q3 Earnings Report

pfizer logoFiercePharma says: The good news: Pfizer delivered a big increase in third-quarter profits; 26 percent, to be exact. The bad: revenues slipped 3 percent, highlighting the fact that cost-cutting boosted earnings, not product performance. (Nonetheless, sales did beat analyst estimates.) Read more of our coverage here...

Highlights:

  • Third-Quarter 2009 Revenues of $11.6 Billion
  • Third-Quarter 2009 Reported Diluted EPS(1) of $0.43, Adjusted Diluted EPS(2) of $0.51
  • Continues to Execute on Financial and Strategic Commitments; Commenced Wyeth Integration on October 16, 2009 Following Completion of the Acquisition
  • Updates Full-Year 2009 Revenue, Reported Diluted EPS(1) and Adjusted Diluted EPS(2) Guidance to Reflect Wyeth Acquisition

Check out Pfizer's current earnings estimates from CNN Money

Pfizer's Website http://www.pfizer.com/home/

Pfizer Q3 Results - Q3 Top Pharma Company Earnings Reports
Read more on

Suggested Articles

While Lilly's 2018 launch Emgality is approved to prevent migraines, Reyvow is intended to treat them as they occur.

ICER's new draft review of RA drugs takes a different approach, reflecting how physicians treat the disease and the time horizon that's considered.

Johnson & Johnson is facing multibillion-dollar liabilities in thousands of talc and opioid cases. But that's not such a bad thing, one analyst said.